Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
DeviceTrident® Ceramic Insert/Trident® AD HA Acetabular Shell
NCT Number: NCT00960206
The purpose of the Post Approval Study of the ABC and Trident® systems is to continue to demonstrate the safety and efficacy of the alumina-on-alumina bearing surfaces combined with the appropriate shell in a cementless application.
Looking for future studies?
Notify Me21 year–75 year
All sexes
Interventional
Not applicable
Orthopaedic Surgery Associates, Boca Raton, Florida, United States
The ABC/ Trident® study was initiated in 1996 as an FDA IDE pre-market study in the United States for alumina bearing THR. PreMarket Approval (PMA)application was approved in February 3,2003. The Post Approval Study (PAS) involved six surgeon investigators from the original IDE study. Subjects who consented to participate in the Post Approval Study continued to be followed to collect limited patient reported data regarding status of the hip.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
Time frame: 10 years
The number of hips in which the study device was removed and replaced with a new component/s is listed. Complications (adverse events) are listed in the adverse event section.
Time frame: 3-5 and 10 Years
Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score less than or equal to 79 is considered fair-poor.
90 - 100 = excellent
80 - 89 = good
70 - 79 = fair
0 - 69 = poor
Time frame: 3-5 and 10 years
Failure is defined as progressive femoral radiolucency (RLL) > or = 2mm around entire stem, progressive subsidence > or = 5mm, progressive acetabular radiolucency (RLL) > or = 2 mm around entire cup, or cup migration > or = 3mm.
Time frame: 6-10 years
A three question follow-up questionnaire was administered annually asking whether the participant is satisfied with the study total hip replacement(THR) (noted as "satisfied" below); whether they have any study hip pain (noted as "no pain" below); and whether they have had any surgery on the study hip during the previous year noted as "no surgery" below).
Stryker Orthopaedics
Industry
Post-Approval Study of the ABC and Trident® Systems
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06102811
Arthroplasty, Replacement, Hip
Toronto, Ontario, Canada
View Trial DetailsNCT07431138
Arthroplasty, Replacement, Hip, Postoperative Evaluation
Ankara, Yenimahalle, Turkey (Türkiye)
View Trial DetailsNCT02520544
Arthroplasty, Replacement, Hip
Antwerp, Belgium
View Trial DetailsNCT07124819
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Bryansk, Russia
View Trial Details